News | April 25, 2023
Tricog raises US$ 8.5 million in series B2 funding
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
Move to increase affordability and accessibility for heart failure patients across the country
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health
Subscribe To Our Newsletter & Stay Updated
